GRAIL raises $325 million in private placement financing
Get Alerts GRAL Hot Sheet
Join SI Premium – FREE
GRAIL Inc. (NASDAQ: GRAL) announced it has entered into a securities purchase agreement for a private placement expected to generate gross proceeds of approximately $325 million before deducting placement agents' fees and other expenses.
The private placement includes participation from new and existing institutional investors, including Deep Track Capital, Farallon Capital Management, Hims & Hers, Braidwell LP, three life sciences investment firms, and a tech and life sciences focused family office investment firm.
Under the agreement, GRAIL will issue and sell 4,639,543 shares of common stock or pre-funded warrants at $70.05 per share. The pre-funded warrants carry a nominal exercise price of $0.001 per share. The private placement is expected to close on October 21, 2025, subject to customary closing conditions.
The company plans to use net proceeds to fund commercial activities and reimbursement efforts, as well as for working capital and general corporate purposes. GRAIL stated its cash, cash equivalents and investments, including the expected net proceeds from this private placement, will provide sufficient funding for planned operations into 2030.
This funding timeline excludes a previously announced agreement by Samsung C&T and Samsung Electronics to invest $110 million in the company, which remains subject to closing conditions.
Morgan Stanley served as lead placement agent and Goldman Sachs & Co. LLC acted as joint placement agent for the transaction. The securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States except under an effective registration statement or applicable exemption. GRAIL has agreed to file a registration statement with the Securities and Exchange Commission for the resale of shares issued in the private placement.
GRAIL develops cancer detection technology using next-generation sequencing and machine learning to identify multiple cancer types in earlier stages.
You May Also Be Interested In
- EShallGo closes $1.75M registered direct offering at $1 per share
- Ensign Group expands credit facility to $800M, extends to 2031
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Goldman Sachs, Morgan Stanley, Farallon Capital ManagementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share